Restore Medical

Catheter-delivered Implant for Congestive Heart Failure

Health Tech & Life Sciences
Active
Series B Or Yehuda Founded 2015
Total raised
$29.4M
Last: Series B 2025-07
Stage
Series B
Founded
2015
Headcount
14
HQ
Or Yehuda
Sector
Health Tech & Life Sciences

About

Restore Medical is dedicated to improve the treatment of congestive heart failure (CHF) by developing innovative and disruptive medical device that will reduce hospitalizations, mortality, and morbidity. The company has developed the first and only transcatheter Pulmonary Artery Banding (PAB) system for the treatment of HFrEF patients.

ContraBand is an innovative and reversible therapy for the treatment of left ventricle (LV) failure. The catheter-delivered implant is designed to leverage the right ventricle (RV) to provide support to the LV, improving LV ejection fraction and restoring optimal ventricular geometry. With no approved treatments currently available for this condition, ContraBand has the potential to transform the way congestive heart failure (CHF) patients are treated.

Ongoing Clinical trial have demonstrated that ContraBand is a highly effective and safe treatment for patients with LV failure. The implantation procedure for ContraBand is simple and time effective.

Funding history · 4 rounds · $29.4M total

2025-07
Series B $23.0M
2023-03
Series A $1.3M
2022-03
Series A $1.5M
2020-03
Series A $1.0M

Sectors & technology

Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesMedical DevicesMedical Treatment & Therapeutics
Technologies
Materials & SubstancesImplants
Target customers
Healthcare & Life SciencesHealthcareProviders
Business model
B2B

Highlights

1 Patents

Tags

cathetershospitalsmedical-devicescardiologyheart-failure